In recent years, with the continuous development and clinical application of ALK- TKI, the progression-free survival (PFS) and overall survival (OS) of intracranial diseases with ALK-NSCLC brain metastasis have been significantly prolonged,[11] but how to use each generation of ALK-TKI reasonably and effectively to treat patients with NSCLC brain metastasis is worth exploring. This evidence concerns the gene ALK and non-small cell lung carcinoma.